US › Healthcare

Milestone Pharmaceuticals Inc (MIST)

US · Healthcare · Biotechnology

$0.71-11.07%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$559,000

Net profit

$-28.6M

EPS

$-0.21

EPS estimate

$-0.18

Net margin

-5,118.8%

EPS came in at -0.21 against a street estimate of -0.18 — a miss of 16.7%.

Key statistics

Market cap

$95.3M

Forward P/E

0.0

P/B

5.89

Book value

$0.13

EPS (TTM)

$-0.66

52-week high

$3.06

52-week low

$0.71

50-day MA

$1.01

200-day MA

$1.47

Beta

1.01

Analyst view

Analysts rate Milestone Pharmaceuticals Inc a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $5.86.

Shareholding

Insiders

0.70%

Institutions

51.50%

Largest institutional holders

Fund	Stake
Pavaki Capital Management LLC	7.28%
RTW INVESTMENTS, LLC	6.29%
Propel Bio Management LLC	5.97%
Point72 Asset Management, L.P.	4.35%
Simplify Asset Management Inc.	2.69%
Millennium Management LLC	2.52%
Kalehua Capital Management LLC	2.04%
Two Sigma Investments LLC	1.64%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Milestone Pharmaceuticals Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.